PRIMARY STUDY
Novel selective agonist of GPR18, PSB-KK-1415 exerts potent anti-inflammatory and anti-nociceptive activities in animal models of intestinal inflammation and inflammatory pain
Key Findings: Resulting data suggests that modulation of GPR18 (via agonist PSB-KK-1415 and antagonist PSB-CB5) is worth considering as a potential treatment target in intestinal inflammation and inflammatory pain.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Poland
Year of Pub: 2021
Cannabinoids Studied: Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: GPCR 18
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
Citation: Fabisiak A, et al. Novel selective agonist of GPR18, PSB-KK-1415 exerts potent anti-inflammatory and anti-nociceptive activities in animal models of intestinal inflammation and inflammatory pain. Neurogastroenterol Motil. 2021; 33:e14003. doi: 10.1111/nmo.14003
Authors: Fabisiak A, Fabisiak N, Mokrowiecka A, Malecka-Panas E, Jacenik D, Kordek R, Zielińska M, Kieć-Kononowicz K, Fichna J
